Grace Therapeutics, Inc.
GRCE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001444192
In the last 90 days, Grace Therapeutics, Inc. insiders filed 5 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.74M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Grace Therapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 13 | 9 | −4 |
| Shares | 197.4K | 152.1K | −45.3K (−23.0%) |
| Value | $248.8K | $183.7K | −$65.1K (−26.2%) |
New holders (1)
Institutions that held Grace Therapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 1,188 | $1.00K | 0.00% |
Sold out (5)
Institutions that held Grace Therapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Renaissance Technologies LLC | 69,777 | $88.0K |
| Jane Street Group, LLC | 18,403 | $23.0K |
| Two Sigma Securities, LLC | 14,720 | $19.0K |
| Toronto Dominion Bank | 82 | $0 |
| Sargent Bickham Lagudis LLC | 5 | $0 |